ADVA-OPTICAL-NETWORKING
14.10.2021 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that i3D.net has deployed its FSP 3000 TeraFlex™ to enhance the experience of the 50 million online gamers that i3D.net serves every day. The technology enables the leading hosting solutions provider for the gaming industry to meet rising data demand and customer expectation by significantly increasing capacity and reducing latency in its global transport network. ADVA’s highly flexible solution enables i3D.net to harness previously unused spectrum, optimizing all optical paths and unlocking new value in its existing fiber infrastructure. The TeraFlex™ terminal will also benefit i3D.net’s enterprise customers, who will be able to leverage low-latency video conferencing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005058/en/
“As one of the world’s leading high-performance hosting providers, we’re constantly striving to deliver an unbeatable experience for end users. That means investing in the most advanced technology on the market. With our new infrastructure built on the ADVA FSP 3000 TeraFlex™ , we’re removing any bottlenecks by massively increasing the capacity of our network. And, thanks to its ultra-flexible coherent interfaces with fractional QAM, it ensures maximum data throughput over every link,” said Edwin Verwoerd, VP, engineering, i3D.net. “Low latency is our business, and that’s precisely what our new solution offers. It enables us to provide a winning edge to both players and businesses.“
i3D.net’s specific configuration of the ADVA FSP 3000 TeraFlex™ is able to carry up to 400Gbit/s of data per wavelength and 800Gbit/s per sled. This open and ultra-flexible 1RU terminal uses software-defined fractional QAM modulation and adaptive baud rate capabilities. As well as significantly boosting the capacity of i3D.net’s worldwide infrastructure, the ADVA FSP 3000 TeraFlex™ ensures the lowest cost per bit for every fiber path. What’s more, it offers advanced streaming telemetry. This provides operators with real-time performance data, helping them to ensure the highest levels of availability and quality of service for end users. The new solution also features other components of ADVA’s FSP 3000 open optical transport solution , including FSP 3000 QuadFlex™ optical terminals.
“Our FSP 3000 TeraFlex™ will be a vital tool for i3D.net. It will be key to seizing new opportunities during the global gaming boom and providing unprecedented levels of quality for its customers. The innovative terminal offers excellent space- and power-efficiency while maximizing fiber utilization. With its flexible bandwidth modulation, it ensures optimal performance even over long-distance links. That’s why our high-performance TeraFlex™ is ideal for supporting satisfying, immersive gaming,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “It’s great to see another major operator harnessing our TeraFlex™ technology to unlock extra value in its infrastructure. Spread across six continents, i3D.net’s network will now deliver even more for its customers.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About i3D.net
i3D.net – a Ubisoft company, is one of the leading providers of high-performance hosting and global infrastructure services. We operate a global low-latency network with thousands of servers spread over 40+ point of presence on 6 continents. i3D.net excels in the gaming market and hosts a variety of AAA games. Our mission is to bring the lowest latency to as many users around the world as possible, with the goals of reaching 1 billion users on our platforms by 2025. For more information visit www.i3d.net .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom